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Critical Care after Lung Transplantation
Since the first successful lung transplantation in 1983, there have been many advances in the 
field. Nevertheless, the latest data from the International Society for Heart and Lung Trans-
plantation revealed that the risk of death from transplantation is 9%. Various aspects of post-
operative management, including mechanical ventilation, could affect intensive care unit 
stay, hospital stay, and immediate postoperative morbidity and mortality. Complications such 
as reperfusion injury, graft rejection, infection, and dehiscence of anastomosis increase fatal 
adverse side effects immediately after surgery. In this article, we review the possible immedi-
ate complications after lung transplantation and summarize current knowledge on preven-
tion and treatment.
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INTRODUCTION 
Immediate postoperative management of lung transplant recipients consists of ventilator 
support and weaning, sedation and pain control, meticulous fluid management, close he-
modynamic monitoring, primary graft dysfunction (PGD) or other organ dysfunction, such 
as acute kidney injury or heart failure. Lung transplantation is a major operation, and various 
technical surgical complications may occur in the early postoperative period. In order to ease 
a patient’s return to normal daily life after lung transplantation, rehabilitation and education 
should be added to the postoperative care plan. However, here we will only cover the imme-
diate postoperative complications and the strategies for the prevention of various complica-
tions. 
IMMEDIATE POSTOPERATIVE MANAGEMENT OF LUNG  
TRANSPLANTATION
Medical Complications 
Primary graft dysfunction
PGD after lung transplantation represents the multifactorial injury of the transplanted lung 
that occurs within first 72 hours after transplantation. PGD is the preferred term and is some-
times referred to as “ischemia-reperfusion injury,” “early graft dysfunction,” and “reimplanta-
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tion edema.” Hypoxia occurring within the first 72 hours after 
lung transplantation and diffuse opaque radiographic ap-
pearances of unknown cause are called PGD. A typical histo-
logic finding is diffuse alveolar damage. The definition pro-
posed by the International Society for Heart and Lung Trans-
plantation (ISHLT) in 2016 is shown in Table 1 [1]. 
 The severity of PGD is evaluated based on the oxygenated 
artery fraction (PaO2/FiO2 ratio, PF ratio), and if there is no dif-
fuse pulmonary edema on chest X-ray, all PF ratios are con-
sidered to be grade 0. The PF ratio is ideally measured at a pos-
itive end-expiratory pressure (PEEP) of 5 cm H2O at FiO2 of 1.0 
and may need correction at elevated altitudes. All measure-
ments of PGD are performed four times, and reperfusion time 
of the second lung (T0), 24 hours, 48 hours, and 72 hours (T24, 
T48, T72). The PGD score at 72 hours may be the most impor-
tant time-point for predicting survival [2]. In terms of treatment 
and prognosis, most patients who maintain normal pulmo-
nary artery pressure, usually of PGD grade 2 or lower, could 
improve with conventional therapy, such as a protective lung 
ventilation strategy and conservative fluid management. In-
haled nitric oxide (iNO) may be used in patients with severe 
PGD (grade 3) whose oxygenation is not improving, despite 
conservative treatment and the maintenance of pulmonary 
arterial hypertension, although the effect of iNO has not yet 
been proven [3,4]. However, there is no evidence that the use 
of iNO prevents PGD [5]. For severe PGD patients not respond-
ing to iNO and general treatment, it is advisable to initiate ex-
tracorporeal membrane oxygenation (ECMO) within 24 hours 
of severe PGD, and most patients will improve with venove-
nous ECMO [6-8]. Prognosis is poor when retransplantation 
for PGD, and most transplantation centers try to avoid retrans-
plantation [9,10]. PGD is considered a risk factor for chronic 
lung allograft dysfunction (CLAD), reoperation rate, longer 
ventilator application, longer intensive care unit (ICU) stay, 
and higher rate of renal replacement therapy; in principle, it is 
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best to prevent PGD rather than to treat it [11-15]. The selec-
tion of adequate donor lungs and optimization of preservation, 
storage, and intraoperative efforts to reduce ischemia-reper-
fusion injury is the best strategy to prevent PGD. 
Acute rejection 
Acute rejection in lung transplantation is still a problem de-
spite aggressive immunosuppressive regimens. Acute rejec-
tion is relatively common, especially in the first post-trans-
plant year. International registry data have reported the per-
centage of acute rejection as approximately 28% [16] and Ko-
rean registry data have reported approximately 21% [17]. The 
problems of acute rejection include not only early graft loss 
and mortality but also initiation of CLAD. 
 Clinical manifestations tend to be nonspecific, including 
cough with or without sputum, dyspnea, mild fever, malaise, 
or pleural effusion without definite evidence of infection or 
other causes [18]. Suspicion of acute rejection is important 
because there are no specific diagnostic tools. Chest X-ray or 
high-resolution computed tomography (CT) findings are also 
nonspecific, consisting of bilateral ground glass opacities of 
lower lobe predominance, interlobular septal thickening with-
out consolidation, atelectasis, or cardiomegaly [19,20]. 
 Acute rejection can be categorized in acute cellular rejec-
tion (ACR) and acute antibody-mediated rejection (AMR). 
The findings of perivascular and peribronchial lymphocytic 
infiltration in transbronchial biopsy confirm ACR. Prompt 
management of ACR is important, and treatment generally 
consists of a 3-day, high-dose, intravenous administration of 
methylprednisolone with optimizing immunosuppression 
[18]. AMR is related to antibodies in lung allografts, and this 
concept evolved as concept of CLAD. The lack of standardized 
data available for the establishment of diagnostic criteria and 
proper treatments for AMR have been the greatest difficulties. 
Therefore, ISHLT published a consensus document on pul-
monary AMR which showed that measurable allograft dys-
function and the presence of circulating donor-specific anti-
bodies and positive C4d peritubular capillary staining should 
be considered diagnostic of AMR [21,22]. Treatment options 
Table 1. The 2016 International Society for Heart and Lung Trans-
plantation definition of PGD
Gradea Pulmonary edema on chest X-ray PaO2/FiO2 ratio
PGD grade 0 No Any
PGD grade 1 Yes >300
PGD grade 2 Yes 200–300
PGD grade 3 Yes <200
PGD: primary graft dysfunction; PaO2: partial pressure of arterial oxy-
gen; FiO2: fraction of inspired oxygen. 
aPatients with no evidence of pulmonary edema on chest X-ray are con-
sidered grade 0. The grade of severity was categorized according to the 
PaO2/FiO2 ratio.
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for AMR include intravenous immunoglobulin, plasmaphere-
sis, or anti-CD 20 monoclonal antibodies; however, the treat-
ment of AMR is still challenging [18]. The response to treat-
ment of AMR can be complete, partial, stabilized or there may 
be no response to treatment [22]. 
Postoperative infection 
Infectious complications represent one of the most important 
causes of adverse outcomes in lung transplantation. Compared 
with other solid organ transplants, reasons for the high sus-
ceptibility to infection unique to lung transplantation are the 
continuous and direct exposure of the lung to environmental 
pathogens, denervation of the allograft—which destroys host 
defense mechanisms, such as the cough reflex—and the trans-
mission of infection from the donor lung [23].
Surgical Complications
Postoperative hemorrhage
Postoperative hemorrhage was once one of the most com-
mon complications (Figure 1). In the early lung transplanta-
tion program, hemorrhage was a common complication, re-
quiring about 25% of reoperation patients after cardiopulmo-
nary bypass, en bloc bilateral lung transplantation. However, 
posterolateral thoracotomy for single lung transplantation 
and clamshell incision for bilateral lung transplantation have 
been effective in securing vision and reducing bleeding. In 
addition, ECMO for intraoperative hemodynamic support, in-
stead of the conventional cardiopulmonary bypass, reduced 
the amount of intraoperative and postoperative bleeding by 
decreasing the dose of heparin [24,25]. 
Large airway complications 
Airway complications are major causes that deteriorate the 
clinical outcomes of recipients. There are several factors in-
volved in large airway complications that occur after lung trans-
plantation, such as interruption of bronchial circulation, air-
way colonization and infection, and immune responses to 
airways. Bronchial stenosis is the most frequent airway com-
plication and is usually seen within 2 to 9 months after trans-
plant, with an incidence of between 1.6% and 32% [26]. It is 
mostly observed at the surgical anastomosis and, on occasion, 
can occur distally. The right side is more frequently affected. 
Bronchial stenosis may be asymptomatic or show symptoms 
of declining expiratory flows, dyspnea, cough, or pneumonia. 
Stenosis is diagnosed by visual inspection with serial flexible 
bronchoscopy. Chest CT is useful for characterizing stenosis. 
Several interventions, including ballooning, inserting stents, 
and surgical brachioplasty have been used to improve symp-
toms [27,28]. Bronchial necrosis and dehiscence is a rare com-
plication with an incidence of between 1% and 10% and is as-
sociated with high morbidity and mortality, often secondary 
to sepsis. Necrosis starts at the mucosa and is visible by flexi-
ble bronchoscopy. Necrosis without dehiscence may be man-
aged by conservative care, with antimicrobials and keeping 
fully expanded lung. Dehiscence starts with signs of pneumo-
mediastinum, subcutaneous emphysema, pneumothorax, 
and new onset of air leakage (Figure 2). A self-expanding met-
al stent can be applied to stimulate granulation tissue and serve 
as a scaffold for healing [29]. However, in case of failure, surgi-
cal repair or pneumonectomy should be considered. Exophyt-
ic granulation tissue narrowing the airway lumen by 25% or 
more may cause respiratory symptoms. Concurrent infection 
with aspergillus may increase granulation [30]. Although re-
currence is common, debridement or brachytherapy have 
been effective in relieving symptoms. 
Vascular anastomotic complications
Vascular anastomotic complications occur in 1.75% of patients 
after lung transplantation [31]. Pulmonary artery and atrium 
anastomosis both can be involved. Donor-recipient size mis-
match, the anastomotic technique, twisting or thrombosis 
may cause these problems. Complications involving the pul-
monary artery are more common (Figure 3). Poor orientation 
of the pulmonary artery and narrowing or kinking due to ex-
cessive length may cause these complications. Vascular com-Figure 1. Gauzes were packed to control postoperative bleeding.
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Figure 2. Bronchopleural fistula (BPF). (A) Fiberoptic bronchoscopy (FOB) finding of BPF (arrows). (B) Suddenly developed pneumothorax 
and subcutaneous emphysema on chest X-ray. (C) FOB finding showing repaired BPF with omental flap. (D) Chest X-ray after BPF repair with 
omental flap.
A B
C D
Figure 3. Pulmonary artery stenosis. (A) Pulmonary angiography shows nearly total obstruction (kinking) of left main pulmonary artery. (B) 
A stent was inserted on left main pulmonary artery and left pulmonary flow was restored. 
A B
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plications should be suspected when the patient shows unex-
plained hypoxemia or pulmonary edema. Chest CT or perfu-
sion scan should be considered. If diagnosed, surgical revi-
sion or intervention, including stenting or ballooning, can be 
applied. For the early detection of vascular complications in 
the operating room, transesophageal echocardiography is 
useful. 
Postoperative Management
Monitoring
Postoperative monitoring in ICUs is on a continuum with in-
traoperative monitoring. Monitoring in the ICU is essential for 
the diagnosis of the clinical condition of a patient that can 
change rapidly and for the planning of future treatment. Like 
most other centers, our center continues to use pulmonary 
arterial catheter, electrocardiogram, pulse oximetry, manom-
eter, and transthoracic echocardiography immediately after 
surgery. Unlike the operating room, postoperative patients in 
the ICU undergo application of an invasive monitoring device 
for a few days after surgery. As such, medical staff should be 
very cautious about the chance of infection associated with 
invasive monitoring devices. Furthermore, intensivists should 
always be careful that side effects, such as catheter removal, 
do not occur, because the patients move, unlike patients dur-
ing surgery. 
Mechanical ventilation care and ventilator weaning
Major respiratory complications (e.g., atelectasis, pneumonia, 
or respiratory failure) were consistently reported in 15% to 
40% of patients within the first 3 days after thoracic surgery 
[32,33]. The onset of these complications may be associated 
with a unique pattern of recovery of pulmonary function after 
open thoracotomy, which presents with an initial 72-hour 
postoperative delay not seen in other major surgery. Previous 
studies have shown that active pain control, such as thoracic 
epidural, may improve postoperative respiratory function 
[32]. The goal of immediate ventilatory care is to reduce respi-
ratory acidosis and maintain adequate oxygenation. We do 
not routinely monitor end-tidal CO2 but apply it, if necessary. 
Patients are usually kept on mechanical ventilation on the day 
of surgery for monitoring because of the risk of reperfusion 
injury. Chest X-ray and arterial blood gas analysis are performed 
at least twice a day to observe the initial changes closely. There 
is no evidence for which mode is the best for postoperative 
ventilator setting, but controlled ventilation is preferred to 
prevent barotrauma on the bronchial anastomosis site and to 
limit the plateau pressure below 35 mmHg [34]. All recipients 
are ventilated using a lung-protective ventilation strategy, re-
gardless of the nature of the primary disease (emphysema, 
pulmonary hypertension or interstitial lung disease) or the 
type of transplantation (bilateral versus single). Protective 
mechanical ventilation includes PEEP and low tidal volume 
(6 to 8 mL/ideal body weight) with permissive hypercapnia. 
There are no large-scale randomized trials of lung-protective 
ventilation strategies for patients undergoing lung transplan-
tation. PGD within 72 hours after lung transplantation is simi-
lar to acute respiratory distress syndrome (ARDS) clinically 
and histologically, and lung-protective ventilation strategies 
are known to be beneficial to ARDS patients. Therefore, most 
physicians apply a lung-protective ventilation strategy to lung 
recipients. In a recent multinational survey-based study, most 
respondents in 18 countries reported using lung-protective 
ventilation strategies in lung recipients. Low tidal volumes 
were frequently chosen based on recipient characteristics. On 
the other hand, the characteristics of donors are not often con-
sidered [35]. 
 The PEEP level is selected according to the presence or ab-
sence of bronchial fistula [36]. In the presence of bronchial 
fistula, ZEEP (zero end expiratory pressure) is used, and in re-
cipients without bronchial fistula, different levels of PEEP are 
applied. PEEP should be set to maximize alveolar recruitment 
while avoiding over-distention. If the patient is hemodynami-
cally stable and oxygenation is improved adequately (SpO2 
> 90%, while receiving a FiO2 <0.5 and PEEP <5 cmH2O), me-
chanical ventilator weaning should be attempted as soon as 
possible. A 1-hour t-tube challenge test is a convenient and 
economical way to assess the possibility of weaning success 
and to predict potential complications associated with spon-
taneous breathing trials. 
Sedation and pain control
In the latest guidelines for sedation in the ICU, benzodiaze-
pine is no longer recommended as a sole sedative, but it is not 
known which sedative other than benzodiazepine is the best 
[37]. Similarly, there is no evidence on which combination of 
sedatives and analgesics has the best prognosis in patients 
undergoing lung transplantation. According to a recent multi-
center survey, more than half of respondents answered that 
propofol in combination with opiates were preferred over 
other combinations, such as opiates with intermittent benzo-
diazepine. However, approximately 40% reported that there is 
no official drug policy on sedation and analgesia for the trans-
planted patient [38]. Recently, the use of dexmedetomidine, a 
selective alpha agonist, has been increasing in ICUs. In many 
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previous studies, it was found that dexmedetomidine can re-
duce the incidence of postoperative delirium for adult cardiac 
and non-cardiac surgical patients [39]. In our center, the use 
of dexmedetomidine during spontaneous breathing trials is 
increasing in lung-transplanted patients. Dexmedetomidine 
produces less respiratory depression than other sedatives and 
has antianxiety effects and small analgesic effects in addition 
to its sedative properties, so it can be used safely even after ex-
tubation. 
Postoperative dysrhythmia
Cardiovascular adverse events, including myocardial infarc-
tion and dysrhythmia, are frequent in the immediate postop-
erative period. Atrial fibrillation has been found in about 40% 
of recipients and generally responds well to conventional treat-
ments, such as calcium channel blockers, beta blockers and 
amiodarone. The elderly patients, and the presence of idio-
pathic pulmonary fibrosis, known coronary disease, enlarged 
left atrium, and the use of postoperative vasopressors increase 
the risk of postoperative atrial fibrillation [40]. In our institu-
tion, transesophageal echocardiography is performed in pa-
tients with postoperative cardiovascular adverse events or 
preoperative cardiac comorbidities before ventilator weaning. 
Antithrombotic agents are not routinely used because of the 
risk of bleeding immediately after surgery, but they may be 
used with caution when dysregulated arrhythmia persists.
Fluid management
Fluid management may influence the degree of lung dysfunc-
tion. After lung transplantation, ischemia-reperfusion injury 
increases pulmonary vascular permeability and decreases 
lymphatic drainage, resulting in some degree of pulmonary 
edema [41]. To decrease the postoperative pulmonary vascu-
lar burden, we perform intravenous fluid therapy very restric-
tively and cautiously, to maintain adequate urine output (0.5 
to 1 ml/kg/hr or more), oxygen saturation level (SpO2 > 95% 
or more) and mean blood pressure (65 mmHg or more) [42]. 
Dynamic parameters, such as pulmonary capillary wedge or 
central venous pressure, have traditionally been used to as-
sess adequate fluid balance in the immediate postoperative 
patients. Recently, various minimally invasive hemodynamic 
monitoring devices, including pulse pressure/stroke volume 
variation [43], esophageal doppler [44], and extravascular lung 
water measurement [45], were evaluated for optimizing peri-
operative fluid therapy for major surgery. One thing that is 
clear is that excessive fluid resuscitation or inotropic support 
resulting in a hyperdynamic right ventricle and the exacerba-
tion of lung reperfusion injury should be avoided [46].
Immunosuppressant use and monitoring
Immunosuppressants are important for the prevention of graft 
rejection. Immunosuppressants can be classified as “induc-
tion” and “maintenance.” The purpose of induction therapy is 
to reinforce early immunosuppression and to allow for a less 
toxic maintenance immunosuppressant going forward [47]. 
However, induction therapy is still controversial in patients 
undergoing lung transplantation, and registry data shows that 
induction therapy is used in approximately 60% of transplan-
tation centers [16]. Polyclonal antithymocyte globulin, inter-
leukin-2R antagonists or alemtuzumab can be used for induc-
tion therapy [16].
 The use of maintenance immunosuppressants in lung trans-
plantation generally involves a three-drug regimen and the 
exact composition can vary by transplantation center. The 
three-drug regimen includes a calcineurin inhibitor (CNI; ta-
crolimus or cyclosporine), a corticosteroid and a nucleotide 
blocking agent (mycophenolate mofetil or azathioprine). Re-
cently, the use of a combination of tacrolimus, corticosteroid, 
and mycophenolate has been increasing [16]. 
 In lung transplantation, higher maintenance immunosup-
pression is needed because lung tissues have an apparently 
higher immunogenicity. Therefore, therapeutic drug monitor-
ing (TDM) is important for treatment individualization and 
TDM for CNI is always needed in lung transplantation. The 
target blood concentration for the CNI can be different depend-
ing on the center. Moreover, minimizing the variability of blood 
levels is also needed adding to the maintaining the high mean 
CNI level for reducing the risk of allograft rejection [48]. Vari-
ability in blood concentration can be related to non-adher-
ence with drug guideline, interacting medications (such as 
some types of anti-fungal agents or rifampin), differences in 
the cytochrome P450 enzyme system, changes in the fat con-
tent of meals and changes in gastrointestinal motility [48,49]. 
Infection control: immunization
Candidates for lung transplantation should have their vaccines 
updated as early as possible before transplantation, because 
antibody responses to vaccines are decreased during organ 
failure, and are significantly reduced after transplantation by 
mycophenolate mofetil treatment and advanced age. The op-
timal timing to begin posttransplant vaccination is 6 months 
after transplantation but should be individualized for each 
patient. Lung transplantation candidates without hepatitis A 
or B antibodies are vaccinated prior to transplantation. Before 
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lung transplantation, a 13-valent protein-conjugated pneu-
mococcal vaccine is used for priming, followed 8 weeks later 
by a 23-valent polysaccharide vaccine. Candidates that have 
not received the tetanus, diphtheria, pertussis (Tdap) vaccine 
or are unaware of their Tdap vaccine status are administered 
the Tdap vaccine and a tetanus-diphtheria booster every 10 
years. All lung transplantation candidates and recipients are 
advised to receive annual influenza vaccinations. 
Infection control: prophylactic strategies for postoperative in-
fections
For the prevention of postoperative infections, antibacterial, 
antifungal, and antiviral prophylaxis is administered. Intraop-
erative antibiotic prophylaxis includes cefepime for Gram-neg-
ative coverage, and vancomycin or teicoplanin for Gram-posi-
tive coverage. The cefepime and vancomycin or teicoplanin 
are typically discontinued or de-escalated after 5 days, once 
all intraoperative cultures are finalized as negative.
 Regardless of the cytomegalovirus (CMV) serostatus of re-
cipients and donors, intravenous ganciclovir is given for anti-
viral prophylaxis at a dosage of 5 mg/kg every 24 hours after 
lung transplantation. If the recipient can tolerate oral intake, 
he or she is transitioned to valganciclovir at a dose of 900 mg 
orally daily. The total duration of antiviral prophylaxis is 6 months, 
but in patients who are CMV IgG negative with a CMV immu-
noglobulin G-positive donor, CMV prophylaxis is considered 
for lifetime as tolerated. Ganciclovir and valganciclovir dosing 
is adjusted based on renal function.
 Fungal infections, especially by Aspergillus species, are very 
common. One frequent site of infection is the bronchial anas-
tomosis. For this reason, most centers recommend some form 
of fungal prophylaxis at least during the first 3 months after 
the transplant [50]. Antifungal prophylaxis varies from center 
to center. Azole antifungals or inhaled formulations of ampho-
tericin B are used, depending on the situation. We use itra-
conazole for antifungal prophylaxis during the 6 months after 
transplant. 
 In solid organ transplant recipients, Pneumocystis jirovecii 
infection is associated with a high mortality rate, despite an 
adapted treatment [51,52]. Therefore, P. jirovecii prophylaxis is 
commonly instituted after all solid organ transplants. There 
are different guidelines addressing P. jirovecii prophylaxis af-
ter solid organ transplants and there is no universal consen-
sus on the optimal duration of prophylaxis. The American So-
ciety of Transplantation recommends a general prophylaxis 
for 6–12 months after solid organ transplants. Lifelong prophy-
laxis is recommended for patients after lung or small-bowel 
transplantation, chronic CMV infection, and in all patients with 
a history of prior P. jirovecii infection [53]. In our center, life-
long trimethoprim/sulfamethoxazole (80/400 mg or 160/800 
mg) is administered to prevent P. jirovecii infection after lung 
transplantation.
Venous thromboembolism prevention
Lung transplant recipients are at increased risk for postopera-
tive venous thromboembolism (VTE: deep vein thrombosis 
and pulmonary embolism) [54,55]. Most patients are treated 
with low-dose subcutaneous unfractioned heparin and inter-
mittent pneumatic compression [56], but patients with a his-
tory of previous VTE may require more intensive therapy [57]. 
In general, VTE prevention continues until hospital discharge. 
Surveillance bronchoscopy 
The role of surveillance bronchoscopy for regular biopsy in 
asymptomatic patients receiving lung transplants is still con-
troversial and the strategy depends on the center. Schedules 
of surveillance bronchoscopy are different; however, monthly 
biopsies are performed in the immediate postoperation peri-
od and the interval is increased after 3 months in many cen-
ters. There are some reports that the incidence of asymptom-
atic ACR is up to 25% [58]; therefore, some centers maintain 
strategies for surveillance bronchoscopy. 
CONCLUSIONS
The immediate postoperative period is critical for the man-
agement of patients undergoing lung transplantation. PGD, 
acute rejection, and postoperative infection should be care-
fully monitored. In addition, it is important to understand that 
postoperative hemorrhage, large airway complications, and 
vascular anastomotic complications may occur due to the 
complexity of the lung transplant procedure itself. Therefore, 
intraoperative hemodynamic monitoring should be contin-
ued in the ICU after surgery. Moreover, based on hemody-
namic parameters, meticulous fluid management and me-
chanical ventilation should be performed. The application 
and maintenance of immunosuppressants in patients with 
lung transplantation vary from center to center, but the com-
bination of tacrolimus, corticosteroids, and mycophenolate 
has increased recently. Controlling the plasma levels of im-
munosuppressants is very important for reducing allograft re-
jection. Patients undergoing lung transplantation who are at 
high risk for infection should be preoperatively vaccinated 
and given prophylactic antibiotics after surgery. The risk of 
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PTE is higher than in patients after other major surgery, and 
VTE prevention should be continued during hospitalization. 
The postoperative critical care management after lung trans-
plantation is very complicated; therefore, a careful approach 
is important. For these reasons, a multidisciplinary approach 
is needed, and proper critical care management after lung 
transplantation is essential to improve outcomes. 
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